Business Context and Reporting Period
Company: RXi Pharmaceuticals Corporation (Note: Filing metadata lists "Phio Pharmaceuticals Corp.", but the document text identifies the registrant as RXi Pharmaceuticals Corporation).
Filing Type: Form 8-K (Current Report).
Date of Report: November 14, 2018.
Reporting Period: The filing announces the reporting of results of operations for the quarter ended September 30, 2018.
Key Financial Metrics
The provided text is a cover sheet for a Form 8-K and does not contain specific financial data. It references a press release (Exhibit 99.1) for the actual figures.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Material Changes
The filing text does not provide specific numerical comparisons or material changes versus the prior comparable period. It solely serves to notify the market that results for the quarter ended September 30, 2018, have been reported.
Guidance, Outlook, and Risks
Management Commentary: The filing states that results were reported on November 14, 2018, via a press release attached as Exhibit 99.1.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not treated as "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless expressly stated.
Guidance and Risks: No specific guidance, outlook, risks, or contingencies are detailed in the provided text.
Investor Verification Checklist
- Verify the correct registrant name (RXi Pharmaceuticals Corporation vs. Phio Pharmaceuticals Corp. in metadata).
- Review Exhibit 99.1 (Press Release dated November 14, 2018) for actual revenue, net loss, and cash position figures.
- Confirm the specific operational milestones or clinical trial updates mentioned in the referenced press release.
- Check subsequent filings for any updates to the financial condition reported in this 8-K.